Abstract. The aim of this study was to identify and validate differentially expressed genes in matched pairs of benign and malignant prostate tissue. Samples included 29 histologically verified primary tumors and 23 benign controls. Microarray analysis was initially performed using a sequence verified set of 40,000 human cDNA clones. Among the genes most consistently and highly upregulated in prostate cancer was the ETS family transcription factor ERG (ETS related gene). This finding was validated in an expanded patient series (37 tumors and 38 benign samples) using DNA oligonucleotide microarray and real-time quantitative PCR assays. ERG was 20-to more than 100-fold overexpressed in prostate cancer compared with benign prostate tissue in more than 50% of patients according to quantitative PCR. Surprisingly, ERG mRNA levels were found to be significantly higher in the endothelial cell line, HUVEC, than in the prostate cell lines PC3, DU145 and LNCaP. In situ hybridization of prostate cancer tissue revealed that ERG was abundantly expressed in both prostate cancer cells and associated endothelial cells. The consistency and magnitude of ERG overexpression in prostate cancer appeared unique, but several related ETS transcription factors were also overexpressed in matched pairs of tumor and benign samples, whereas ETS2 was significantly underexpressed. Our findings support the hypothesis that ERG overexpression and related ETS transcription factors are important for early prostate carcinogenesis.
Introduction
Recent DNA microarray based studies have revealed characteristic gene expression profiles associated with either primary prostate cancer or metastasis (1-3), progression to hormone refractory tumors (4), or patient survival (3, 5) . Some of these reports have identified novel and potentially important tumor markers such as ·-methylacyl-CoA-racemase (6) (7) (8) (9) and hepsin (3, (10) (11) (12) (13) . The aim of our present study was to explore the expression profiles of prostate cancer with special focus on important transcription factors. Among the genes most consistently and highly upregulated was the transcription factor ERG (ETS related gene), showing 20-fold to more than 100-fold increased expression of ERG in 50% of prostate tumors (T) compared with benign samples (B).
ERG is one of more than 30 transcription factors belonging to the ETS family, which is defined by a conserved DNA binding domain that recognizes the promoter sequence GGA A /T (14) . ETS transcription factor genes have been acquired and selected for during evolution of oncogenic retroviruses (14, 15) , and they also appear as fusion partners in certain tumor chromosomal translocations (14) . During mammalian embryogenesis, ERG is first expressed in endothelium and later in the kidney, urogenital tract and hematopoietic cells, whereas down-regulation is observed following tissue differentiation (16, 17) . The embryonic activation pattern of ERG is relevant for our present observations that ERG transcription is strongly increased in prostate cancer epithelial cells, and with additional ERG expression in prostate endothelial cells. This upregulation of ERG in prostate cancer may provide an example of oncogenic reactivation of an embryonic transcription factor.
The literature is not consistent regarding the exon mapping of ERG (18) . ERG transcripts from benign prostate hyperplasia were therefore PCR amplified and DNA sequenced. A resulting revised exon map of ERG isoforms 1 and 2 is presented. An ERG isoform 1 specific exon was consistently overexpressed in prostate cancer samples.
ERG overexpression in prostate cancer was distinct compared with other ETS family transcription factors, several endothelial markers and neighbouring genes on chromo-RNA purification, enzymatic modification and fluorochrome labelling. Individual biopsies were ground to powder under liquid N 2 . Total RNA was extracted according to standard protocols (23) (InVitrogen TRIzol LS protocol and Qiagen RNeasy minikit protocol). T7 RNA polymerase promotercontaining double stranded cDNA and T7 RNA polymerase amplified RNA (cRNA) were generated as previously described (22) and according to the Ambion T7 Megakit protocol. Aminoallyl-U (aminoallyl-UTP from Ambion) incorporation into cRNA followed by cross-coupling to Cy5 and Cy3 by means of reactive Cy-NHS compounds (Amersham) was used for fluorochrome labelling of nucleic acids. Cy5 and Cy3 incorporations were measured by absorption readings at 649 and 550 nm, respectively, using a PowerWave Spectrophotometer. Simultaneous recording of absorptions at 260 nm allowed calculation of specific labelling.
DNA microarray. The Research Genetics human 40k cDNA microarray printed at the Institute for Systems Biology, Seattle has been described previously (22) . RNA derived from a pool of 18 cell lines was Cy-labeled in parallel with patient samples and served as reference RNA during cDNA microarray hybridizations. The Agilent human 1A oligonucleotide microarray (21k) was used for validation according to the Agilent protocols except for a more stringent wash (0.X SSC at 25˚C for 10 min). The Stratagene Universal RNA was the reference RNA for Agilent microarrays. The oligonucleotide microarrays were scanned and features automatically extracted, recorded and analysed using the Agilent Microarray Scanner Bundle. Normalization, flooring or filtration of data were done as previously described (22) . Genes were filtered before inclusion in the dataset, and genes were included if the signal intensities in both channels differed >2SE over background in at least 70% of samples in each class (e.g., T or B) (filtered dataset). As filtering may exclude candidate genes expressed in subsets of samples, an alternative method, flooring, was also performed (22) . In the case of low or no signal in at least one channel the log-ratio was based on intensities floored at a value of 20 and included in a second dataset (floored dataset). Data were formatted in a J-Express-file suitable for additional data mining (http://www.molmine.com/) (24) .
Identification of differentially expressed genes. Following normalisation, a Cy5/Cy3 log 2 -ratio was calculated for each feature of the microarray. Average fold change was calculated for each gene. Fold change for gene i was calculated by taking the absolute difference d of the average log-ratio in T and B, and then taking 2
d . In addition we determined the t-score (twosample t-test) of each gene, thus quantifying the distance of the average log-ratios between the groups compared to the spread of log-ratios within each group. A paired t-test was also used.
PCR and real-time quantitative PCR (qPCR).
Single-stranded cDNA for qPCR analysis was synthesised from 50 ng/μl of total RNA using a final concentration of 5 μM random hexamer primers, pd(N) 6 (Amersham Pharmacia Biotech) and M-MLV reverse transcriptase according to Ambion instructions. qPCR reactions were set up in a total volume of 25 μl containing 12.5 μl 2X TaqMan Universal Master Mix, including ROXreference dye, uracil N'-glycosylase (Applied Biosystems), AmpliTaq Gold DNA polymerase (Perkin-Elmer), 900 nM of each primer and 250 nM of FAM-labelled TaqMan probe, and 5-10 ng of total RNA (as hexamer primed ss-cDNA). The mixtures were prepared in 96-well optical microtiter plates and amplified on the ABI7900HT Sequence Detection System using the following cycling parameters: 2 min at 50˚C, 10 min at 95˚C, and 40 alternate cycles of 15 sec at 95˚C and 60 sec at 60˚C. Serial dilutions of pooled prostate cDNA were used for the generation of standard curves for each TaqMan assay including the endogenous control. Each sample cDNA was tested in triplicate. The SDS2.2 software was used for analysis and relative quantification according to program manuals and the Applied Biosystems User Bulletin #2. Table I shows the TaqMan Custom made assays (Assay-by-Design) for the detection of ERG sequences and the ß-actin TaqMan assay used as endogenous control for normalization between samples. qPCR in the low density array (LDA) format. Low density arrays (LDA) are customisable, 384-well microfluidic cards for real-time qPCR (Applied Biosystems). Each LDA card was configured for 95 different genes in duplicates including Celera gene ID: -hCG401221 v-ETS erythroblastosis virus E26 oncogene like (avian) (ERG). This TaqMan assay targets nucleotide position 330 of NM_182918 (ERG1) and position 444 of NM_004449 (ERG2). Hexamer-primed single stranded cDNA corresponding to 5 ng of prostate total RNA was diluted in TaqMan Universal buffer (Applied Biosystems) and added to each loading well. Using the above configuration each sample occupied 4 wells or one half of each card. The samples were distributed to the microwells by centrifugation for 1 min at 343 x g. The cards were sealed and placed in the ABI 7900HT Sequence Detection System using the following cycling parameters: 2 min at 50˚C, 10 min at 95˚C, and 40 alternate cycles of 15 sec at 95˚C and 60 sec at 60˚C. The SDS2.2 software was used for qualitative analysis and data were exported to Excel for further exploration and visualization.
DNA sequencing of ERG1 and ERG2 isoforms. Specific cDNA was made from 2 μg total RNA in 20 μl 1X first strand buffer with 0.01 M DTT, 0.5 mM dNTPs, 1.0 μl RNaseOUT (Invitrogen), 2.0 μl Superscript III RT (Invitrogen) and 2.0 μM ERG reverse oligo primer. The cDNA synthesis was performed at 50˚C for 90 min. cDNA (1.5 μl) was amplified using 1X HotMasterMix (Eppendorf) and 0.2 μM of each forward and reverse primer. PCR amplification was performed with an initial denaturation at 95˚C for 10 min followed by 40 cycles at 94˚C for 15 sec, 58˚C for 20 sec and 72˚C for 40 sec. PCR product (5 μl) was mixed with 2 μl Exo-SAP-IT (USB) for removal of unincorporated dNTPs and primers. The Exo-SAP clean up was done at 37˚C for 15 min followed by enzyme inactivation at 80˚C for 15 min. Cleaned PCR product (3.5 μl) was mixed with 1 μl BigDye Terminator v1.1 (Applied Biosystems), 2 μl 5X BigDye Terminator sequencing buffer and water to a final volume of 10 μl with 210 nM of forward and reverse primers. The reaction was run at 96˚C for 1 min followed by 25 cycles at 96˚C for 10 sec and 58˚C for 5 sec followed by 60˚C for 4 min. The sequence reaction was analysed on a 3100 Genetic Analyser (Applied Biosystems).
Cell culture and cell lines. The cell lines SaOS-2 (osteosarcoma derived), HLF (human lung fibroblasts), HUVEC (human endothelial cell line) and the prostate cancer cell lines PC3, DU145 and LNCaP were obtained from the American Type Culture Collection (ATCC, Rockwell, MD, USA). SaOS-2 monolayers were grown in McCoy medium (BioWhittaker) with 2 mM glutamine. All media contained 5-10% fetal calf serum (BioWhittaker) and 100 μg/μl gentamicin (BioWhittaker). The EGM-2 bullet kit (BioWhittaker) was used for HUVEC monolayers. Iscove's modified Dulbecco's medium (IMDM) (BioWhittaker) with 25 mM HEPES and 2 mM glutamine was used for HLF, DU145 and LNCaP monolayers. PC3 monolayers were grown in HAM's F12K (BioWhittaker) with 2 mM glutamine. The cell monolayers were harvested in TRIzol LS. RNA was extracted according to the InVitrogen TRIzol LS protocol. The cell lines CRL-2392 (GA10, Burkitt lymphoma, human) and CRL-1593.2 (U937, histiocyte human) obtained from ATCC were grown in suspension in IMDM with 25 mM HEPES and 2 mM glutamine and were harvested by centrifugation at 840 x g for 5 min. Prior to lysis in TRIzol LS the cells were gently resuspended in 500 μl of 0.9% NaCl and RNA was extracted according to the InVitrogen TRIzol LS protocol. The pellet following isopropanol precipitation was dissolved in RLT ß-mercaptoethanol buffer (Qiagen) and total RNA was extracted according to the instructions enclosed with the Qiagen RNeasy minikit.
RNA probe synthesis and in situ hybridization. T3-and T7-containing Bluescript SK -ERG/Actin plasmids (Invitrogen) were used for synthesis of DIG-RNA ERG antisense, ERG sense and ß-actin antisense probes, respectively. Plasmids were cut with restriction enzymes and then sequenced to verify the specificity of the sequence. MEGAscript High Yield Transcription Kit T3/T7 (Ambion) was used for RNA synthesis.
The synthesis was performed with 1 μg DNA and 1.9 mM ATP/CTP/GTP, 1.3 mM UTP, 0.7 mM DIG-UTP and buffer and enzyme mix according to the kit manual (Ambion) at 37˚C for 4 h. The DIG-cRNA was next fragmented to 60-200 long nucleotides using RNA Fragmentation Reagents according to the manual (Ambion).
Slides with paraffin embedded tissue were incubated at 65˚C for 1 h, deparaffinized 5 min twice in xylene and re- Table I . TaqMan assays used for the quantification of ERG1 and ERG2 mRNA isoform specific exons, ERG common exons and the endogenous ß-actin mRNA.
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a Accession nos. and nucleotide positions are shown for primers and probes. F, sense primer; R, antisense primer; FAM, fluorochrome label.
hydrated 5 min twice in 100% ethanol followed by 5 min in DEPC-H 2 O. Slides were boiled in citrate buffer for 20 min and then treated with 0.2 M HCl and 0.25% acetic anhydride for 15 min each. Fragmented DIG-labelled probes were mixed with hybridization solution (Sigma) to 20 ng/μl, added to slides and incubated 12 h at 42˚C. Post-hybridization wash was done twice in 2X SSC at 52˚C for 10 min. Unbound probe was removed using 10 μg/ml RNase at 37˚C for 10 min followed by 2X SSC/50% formamide at 42˚C for 10 min to refix. Slides were blocked with 2% horse serum for 30 min before incubation with anti-DIG-AP Fab fragments diluted 1:250 overnight at 4˚C. Staining was done with liquid permanent red chromogen (LPR) for 5-20 min (Dako) and counterstaining with hematoxylin. were examined (22) . Some variation was found among gene lists based upon floored or filtered data used in either paired or unpaired t-tests and ranked according to either t-score or fold change. A disadvantage with filtered data is the possible removal of genes that are not expressed in benign tissue, or expressed in only a minor subset of the tumors. Table II was based upon a floored dataset (floored at a value of 20) and the unpaired t-test included all 29 Ts and 23 Bs. The genes were ranked according to fold change and Table II confirmed several previous publications regarding AMACR (9, 10) , T cell receptor Á locus (9, 25) , AGR2 (26, 27) and hepsin (3,10-13).
Results

Differential gene expression of malignant and benign prostate
We were also able to confirm the overexpression of SIM2 in a subset of prostate cancers (28) (29) (30) . Many ESTs were differentially expressed (Table II) . 
Validation of ERG overexpression in
a Genes were ranked according to average fold change between T and B based upon an unpaired t-test of a floored dataset.
-
revised exon map is shown in Fig. 1 and is consistent with the GenBank Accession nos. NM_182918 (ERG isoform 1) and NM_004449 (ERG isoform 2).
Expression of ERG isoform specific exons in different prostate
samples. Eleven paired T/B prostate samples, supplemented with one solitary T, were examined using TaqMan qPCR assays specific for the most 3' ERG1 specific exon (NM_182918) and a more 5' ERG2 specific exon (NM_004449) (Fig. 1 , Table I ). A low level expression of both ERG1 and ERG2 specific exons were detectable in benign samples (Fig. 2) Table I ). A control sample of benign prostate hyperplasia (BPH) revealed moderate expression of both ERG1 and ERG2 isoform specific exons, but 4-fold higher expression of ERG1 than ERG2 exons (Table III) .
Expression of ERG isoforms in different cell lines.
A preferential endothelial expression of ERG has been reported (31-33). As one initial approach to define the cell type specific 
a ß-actin was used for normalization between samples. All samples were examined in triplicates.
of ERG a panel of endothelial (HUVEC), mesenchymal (HLF, SaOS-2), lymphoid (GA10, U937) and prostate cancer (PC3, DU145, LNCaP) cell lines were examined using qPCR (Table III) . The ERG1 specific exon was over 1,000-fold more abundant than the ERG2 specific exon in HUVEC cells. SaOS-2, DU145 and U937 contained much lower, but detectable levels of both ERG1 and ERG2 specific exons. In PC3 cells low level expression of only the ERG1 exon was found. Low level expression of exon 1 was also found in HLF. In GA10 and the androgen responsive prostate cancer derived cell line LNCaP neither ERG1 nor ERG2 exons were detectable (Table III) . ERG mRNA was not detected in LNCaP cells stimulated with the synthetic androgen R1881 for up to 48 h using any ERG specific TaqMan assay (results not shown).
Correlation between gene expression of ERG and selected vascular markers. Twenty-two randomly selected prostate samples (4 unpaired prostate cancers and 9 paired T and B samples) were examined using the Agilent human oligonucleotide 1A (v1.0) microarrays (Fig. 3) . A paired t-test including all 9 T/B pairs shown in Fig. 4 revealed that ERG was significantly overexpressed in T compared with B (mean ERG T=13.6, mean ERG B=1.9, P=0.007). The same statistically significant relationship was present in the unpaired t-test including 13 Ts and 9 Bs. Selected endothelial cell markers were analysed (Table IV) . In neither case did T/B ratios of ENG (endoglin/CD105), PECAM1 (CD31), PODLX2 (podocalyxin-like, CD34 family), VWF (von Willebrand factor) or several TEM factors correlate with the T/B ratios of ERG (Table V) . In contrast, the Spearman test revealed several significant correlations between T/B ratios of different endothelial markers (Table V) . In addition, altogether 10 of the prostate T/B pairs previously analysed by microarrays were validated using the Applied Biosystems LDA qPCR format for ENG, PECAM1, PODLX2 and VWF (Table VI) . Again, no significant relationship was evident between ERG overexpression and expression of the vascular marker genes in prostate cancer.
In situ hybridization detects ERG mRNA mainly in epithelial prostate cancer cells but also in endothelial cells.
The detection of ERG-specific mRNA using DIG-labelled antisense riboprobes and in situ hybridization of prostate cancer tissue is shown in Fig. 5 . The corresponding prostate cancer tissue expressed abundant ERG mRNA according to microarray and real-time qPCR analysis. A ß-actin riboprobe control showed extensive staining of all cell types of the sections (data not shown). The malignant prostate glands contained abundant ERG mRNA in the epithelial cytoplasm (Fig. 5) while the benign glands were negative or only weakly positive. In addition ERG mRNA was clearly detected in endothelial cells (Fig. 5) .
Correlation between microarray expression data of ERG and other ETS family transcription factors.
Agilent microarray expression data were available for 20 different ETS transcription factors (Table VII) . No case of overexpression in prostate cancers (high T/B among the 9 pairs) was evident for 11 of the 20 ETS factors. The 3 out of 9 T/B pairs lacking increased ERG instead overexpressed alternative ETS transcription factors (Table VII) . ELF5 exhibited elevated T/B expression ratios in patients 2.4P54, 2.2P33 and 4.8P85, respectively (Fig. 4 , Tables VI and VII). ETV1 T/B was elevated in 4.8P85, and ETS1 T/B was elevated in 2.4P54 (Table VII) . A Spearman test was conducted for the correlation of T/B ratios between the 9 paired Ts and Bs of different ETS family transcription factors (Table VII) . The results (Table VIII) showed a negative correlation between ELF5 T/B and ERG T/B ratios (Spearman correlation coefficient = -0.72, P=0.03), between ETV1 T/B and ERG T/B ratios (Spearman correlation coefficient = -0.61, P=0.08) and also between ETS1 T/B and ERG T/B ratios (Spearman correlation coefficient = -0.72, P=0.03). The Spearman test revealed that ERG T/B was not positively correlated at a significant level to any other ETS transcription factor T/B ratios. The ELF5 oligonucleotide microarray data were validated using LDA qPCR and high T/B ratios of 13.6, 2.6 and 6.6 were found for 2.4P54, 2.2P33 and 4.8P85, respectively. Moderately high T/B ratios of ELF3 were also verified using LDA qPCR (Table VI) . ERG oligonucleotide microarray T/B ratios corresponded well to LDA qPCR T/B ratios taking into consideration that especially high ratios are compressed in DNA microarrays compared with qPCR analysis (Table VI) (34, 35) .
Down-regulation of ETS2 in matched prostate T/B pairs
according to microarray data. ETS2, which also belongs to the ETS family of transcription factors and is the closest mapped gene upstream of the ERG transcription initiation site, is noteworthy. ERG and ETS2 are transcribed in opposite directions and both have promoters within the same region of less than 150,000 bp of chromosome 21q22. Seven of nine T/B pairs, including all with high ERG T/B ratios, displayed negative to very negative ETS2 T/B ratios (Fig. 4) . A paired t-test including all 9 T/B pairs shown in Fig. 4 revealed that ETS2 was significantly underexpressed in T compared to B (mean T=1.41, mean B=3.13, P=0.029). The same relationship -
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was present in the unpaired t-test including all 13 Ts and all 9 Bs of the Agilent oligoarrays (mean T=1.68, mean B=3.13, P=0.04). There was, however, no significant correlation between the T/B ratios of ERG and ETS2 (Table IX) . Table IV ).
Correlation between gene expression of ERG and neigh-
- Spearman's  Correlations  rho  PECAM1 TEM5  FLT1  CD34  TEM7R TEM7 PODLX2 TEM1 VWF  FLT4 PECAM12 ERG - 
----------------------------------------------------------------------------------------------------
Correlation is significant at the 0.05 level (2-tailed); b Correlation is significant at the 0.01 level (2-tailed). Correl. coeff., correlation coefficient.
and T samples compared with the Stratagene U cell pool RNA (Fig. 3) .
Discussion
ERG was among the most consistently and highly expressed transcription factors in prostate cancer compared with benign tissue, and very high ERG T/B expression ratios (above 20) were found by qPCR in 14 of 27 patients for which paired tumor (T) and benign tissue (B) samples were available. Recently, one independent work has reported ERG overexpression in prostate cancer (20) . Overexpression of ERG has further been reported in acute myelogenous leukemia (AML) (36) and in megalokaryoblastic leukemia (37) . A plausible - - 
----------------------------------------------------------------------------------------------------B, Expression of ERG exons in malignant (T) versus benign (B) samples (T/B ratios) using different methods
Comparison of ERG T/B ratios according to different qPCR assays and Agilent 21k oligonucleotide microarrays for 13 of the 27 paired prostate samples of the extended patient series. Amplification and detection was designed for isoform specific exons (ERG1 and ERG2) or for an isoform common exon (ERG) (Fig. 1) . LDA, qPCR low density array. Agilent, 21k human DNA oligonucleotide array.
mechanism of ERG upregulation in prostate cancer has been found, involving a translocation that brings ERG under control of the androgen responsive promoter of a highly expressed prostate protease gene, TMPRSS2 (19) . In Ewing's sarcoma, ERG and FLI-1 DNA-binding domains are involved in defining translocations with the activation domains of RNA-binding proteins like EWS and FUS (38, 39) . The ERG-FUS fusion has also been found in some cases of AML (40) (41) (42) . ERG has been described as an endothelial transcription factor (30) (31) (32) and is expressed during vascular embryogenesis in mice (17) . In our study, ERG mRNA was more abundantly expressed in endothelial (HUVEC) cells than in three tested prostate cancer derived cell lines, including androgen stimulated LNCaP cells. Since gene expression analysis of tissues can be biased by the proportion of different cell types present (43) , both DNA microarray data and real-time qPCR were used to analyse possible coexpression of ERG and various vascular markers, such as PECAM1 (CD31), ENG (endoglin, CD105), PODLX2 (podocalyxin-like) and von Willebrand factor (VWF), but no significant covariation was found. Using in situ hybridization the present work clearly identified the epithelial prostate cancer cells as the main source of ERG mRNA, in accordance with one previous study (20) . The present study in addition shows that ERG mRNA was also expressed by prostate endothelial cells. The pronounced cytoplasmic staining of ERG mRNA indicates the production of functional mRNA. In both prostate cancer tissue and in HUVEC cells an ERG isoform 1 specific exon was overexpressed. Future work will address the different roles of ERG expression in prostate cancer epithelial cells versus endothelial cells.
More than 30 ETS family transcription factors have been identified (14) . Oligonucleotide microarray expression values were available for 20 of these factors including ERG. Most ETS factors were not elevated in prostate cancer compared with matched benign tissue, but 3 of 9 patients who did not overexpress ERG showed increased expression of ELF5 with T/B ratios between 2.6 and 13.6 as validated by real-time qPCR. Also, ETV1 and ETS1 were abundantly expressed in some cases lacking ERG overexpression. According to the Spearman test ELF5, ETV1 and ETS1 T/B ratios were inversely related to ERG T/B ratios suggesting that these ETS transcription factors might substitute for ERG in prostate cancer. Prostate cancer TMPRSS2-ETV1 fusions as an alternative to TMPRSS2-ERG fusions were recently reported (19) , and also ETS1 overexpression has been reported in prostate cancer (44) . Very high expression ratios of most ETS transcription factors were found only occasionally and did not match the consistency and magnitude of ERG levels. This observation supports the possibility that ERG is of particular significance in prostate carcinogenesis.
Following the recent publication of Tomlins et al (19) , we re-examined our data and found TMPRSS2 to be abundantly overexpressed in all our T and B samples compared with the cell pool control RNA. Of interest, ETS2 and ERG have their promoters within a common region of less than 150,000 basepairs and are transcribed in opposite directions on chromosome 21q22. Although both are ETS family transcription - - Table VIII . Spearman rank correlation between ERG and ETS transcription factors (data in Table VII ).
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